12/10/2017 20:50:00

CAPS® to Showcase Latest 503B Quality Assurance Capabilities and Expansion Plans at Health Connect Reverse Expo – Fall Hospital Pharmacy Conference

IRVINE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS®), will showcase its sustained commitment to improving patient safety at the 2017 Health Connect Conference in Chicago, IL, Oct. 16-18.

At booth #508, CAPS representatives will introduce the company’s latest 90-Day Beyond Use Dating (BUD) quality assurance offering for pre-filled syringes and other products, which is designed to improve the waste reduction process. This initiative further complements CAPS’ current extended BUD offerings. 

CAPS has been a front-runner in implementing the Food and Drug Administration’s (FDA) 503B quality assurance requirements under the Drug Quality and Security Act. During the conference, CAPS will highlight its Test, Hold and ReleaseSM (THR®) program, which is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for 100% cGMP release testing for sterility, potency, and endotoxin prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.

“Our existing high quality standards are strengthened with THR implementation,” said Mike Koch, Senior Vice President, CAPS Professional Services. “When it comes to patient safety, we believe that 100% release testing from our 503B facilities is the only way to assure the level of quality demanded by our customers.”

CAPS was among the first outsourcing admixture pharmacies in the nation to fully adopt release testing.

“CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment,” said Koch. “Our goal is to provide our customers with programs such as THR, and extended BUD to help them focus on improving patient care.” 

To further underscore its commitment to servicing its customers and expanding its sterile compounding outsourcing services in the U.S., CAPS will open a new 250,000 square-foot, state-of-the-art facility in Phoenix, AZ, which is expected to open in the summer of 2018. The new facility will be registered with the FDA as a 503B outsourcing facility, to distribute compounded sterile preparations. CAPS has two existing 503B facilities located in San Diego, CA and Allentown, PA.

“With the opening of our third 503B facility, CAPS will enhance productivity and increase capacity, while serving as an economic boost to the local and state economy,” said Tom Wilverding, President of CAPS. “When fully operational the CAPS facility will create nearly 400 new jobs including opportunities for pharmacists, pharmacy technicians, chemists, microbiologists, and other support personnel.”

About B. Braun

B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

About CAPS

CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS currently has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.CAPSpharmacy.com.

Contact:    

Todd Jones

Central Admixture Pharmacy Services, Inc. 303.744.7713

Todd.Jones@CAPSpharmacy.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Oct
PNDORA
Har efterhånden læst mange indlæg om Pandora her på Euroinvestor. De fleste indlæg er enten beregne..
21
11 Oct
MATAS
  Jeg har længe fulgt med i Matas’ forretningsmæssige udvikling, fordi selskabet er udsat for mange ..
20
13 Oct
PNDORA
Det ligger klart for enhver at med vaekst rater over 10 procent om aaret, som vedholdende vil blive ..
16
16 Oct
VWS
Kommentarer, hvorfor anvender du nu en periode på 13 måneder, når du ser tilbage for at sammenligne ..
11
17 Oct
I:DAX
Suspenderer sikkert al sikkert al handel i Frankfurt  hvis den falder -0,3% Hvad hedder det så hvis..
10
14 Oct
VWS
Earlier this year, China's National Energy Administration announced it would spend $363 billion by 2..
10
13 Oct
VWS
Kommentarer, du svarede ikke på mit indlæg til dig sidst. Måske du ikke så det? Jeg stillede spørgsm..
10
16 Oct
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
9
16 Oct
VWS
Hej Kommentarer. Dejligt du lige kan påminde os om, hvordan kursudviklingen har været, det har været..
9
15 Oct
VWS
Skotland's nationalist party har i denne uge annonceret at de arbejder frem imod at lave et nyt stat..
9

Admiral Group PLC : Director/PDMR Shareholding

29/09/2017 14:53:59
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1 Details of the person discharging managerial responsibilities (PDMR)/person closely associated with them (PCA) a) Name Annette Court 2 ..

Man Group PLC : Form 8.3 - [Clinigen Group plc]

29/09/2017 12:19:01
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

Invesco Ltd. : Form 8 (DD) - IP Group Plc

29/09/2017 10:46:56
                                                            FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
NAVIENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Navient Corporation - (NAVI)
2
Boston Test of Self-Driving Cars Reveals Five Key Lessons for Cities Worldwide
3
XBT PROVIDER AB - UPDATE IN CONNECTION WITH BITCOIN CASH
4
Plan a Cruise Month, Week Three: Cruise Lines International Association (CLIA) Shines Spotlight on Australasia Cruise Travel
5
Smithfield Foods’ Helping Hungry Homes® and Kroger Donate More Than 39,000 Pounds of Protein to God’s Pantry Food Bank

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 October 2017 04:45:03
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171017.1 - EUROWEB7 - 2017-10-18 05:45:03 - 2017-10-18 04:45:03 - 1000 - Website: OKAY